Tumor necrosis factor (TNF)-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira, biosimilars of both drugs, where available) are the mainstay of biological treatment for moderate to severe ulcerative colitis (UC). However, these agents carry safety risks and have efficacy limitations. Takeda’s Entyvio (a cell adhesion molecule [CAM] inhibitor), Pfizer’s Xeljanz / Xeljanz XR (an oral Janus-activated kinase [JAK] inhibitor), and Janssen’s Stelara (an interleukin [IL]-12/23 inhibitor) have expanded the treatment options for moderate to severe UC, but significant unmet need remains, especially in the treatment of UC patients refractory to these therapies. Several agents in late-phase development, including additional JAK inhibitors, S1P-R modulators, and IL-23 inhibitors, are poised to enter the moderate to severe UC market over the next several years, but whether they will be able to fulfill the unmet need remains to be seen.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European gastroenterologists fielded in March 2021
Key companies: AbbVie, Janssen, Takeda, Pfizer, Eli Lilly, Bristol Myers Squibb
Key drugs: Humira, Remicade, Entyvio, Xeljanz / Xeljanz XR, Stelara, Remsima SC, adalimumab biosimilar